NeuroSigma occupies a valuable niche in pediatric neuromodulation, with trigeminal nerve stimulation for ADHD offering a non-drug option in a population sensitive to medication concerns. Its FDA-cleared position is a meaningful barrier in an otherwise lightly populated segment.